Warning: The NCBI web site requires JavaScript to function. more...
Scar wars: is TGFbeta the phantom menace in scleroderma?
Leask A.
Arthritis Res Ther. 2006;8(4):213. Review.
Related citations
Targeting the TGFbeta, endothelin-1 and CCN2 axis to combat fibrosis in scleroderma.
Cell Signal. 2008 Aug;20(8):1409-14. Epub 2008 Jan 19. Review.
A novel inhibitor of Smad-dependent transcriptional activation suppresses tissue fibrosis in mouse models of systemic sclerosis.
Hasegawa M, Matsushita Y, Horikawa M, Higashi K, Tomigahara Y, Kaneko H, Shirasaki F, Fujimoto M, Takehara K, Sato S.
Arthritis Rheum. 2009 Nov;60(11):3465-75.
Postnatal induction of transforming growth factor beta signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical features of scleroderma.
Sonnylal S, Denton CP, Zheng B, Keene DR, He R, Adams HP, Vanpelt CS, Geng YJ, Deng JM, Behringer RR, de Crombrugghe B.
Arthritis Rheum. 2007 Jan;56(1):334-44.
Mechanisms of skin fibrosis in systemic sclerosis.
Jinnin M.
J Dermatol. 2010 Jan;37(1):11-25. Review.
TGFbeta, cardiac fibroblasts, and the fibrotic response.
Cardiovasc Res. 2007 May 1;74(2):207-12. Epub 2006 Jul 21. Review.
Autocrine TGF-beta signaling in the pathogenesis of systemic sclerosis.
Ihn H.
J Dermatol Sci. 2008 Feb;49(2):103-13. Epub 2007 Jul 12. Review.
Paclitaxel modulates TGFbeta signaling in scleroderma skin grafts in immunodeficient mice.
Liu X, Zhu S, Wang T, Hummers L, Wigley FM, Goldschmidt-Clermont PJ, Dong C.
PLoS Med. 2005 Dec;2(12):e354. Epub 2005 Nov 1.
Systemic sclerosis: an update.
Varga J.
Bull NYU Hosp Jt Dis. 2008;66(3):198-202. Review.
Signaling in fibrosis: targeting the TGF beta, endothelin-1 and CCN2 axis in scleroderma.
Front Biosci (Elite Ed). 2009 Jun 1;1:115-22. Review.
Transforming growth factor-beta signaling through the Smad proteins: role in systemic sclerosis.
Verrecchia F, Mauviel A, Farge D.
Autoimmun Rev. 2006 Oct;5(8):563-9. Epub 2006 Jul 5. Review.
The role of endothelin-1 signaling in the fibrosis observed in systemic sclerosis.
Pharmacol Res. 2011 Jun;63(6):502-3. Epub 2011 Feb 17. Review.
Vascular alterations upon activation of TGFbeta signaling in fibroblasts--implications for systemic sclerosis.
Horn A, Distler JH.
Arthritis Res Ther. 2010;12(3):125. Epub 2010 Jun 18.
[Pathophysiologic aspects of systemic sclerosis].
Gran JT, Molberg Ø, Midtvedt Ø.
Tidsskr Nor Laegeforen. 2005 Oct 6;125(19):2622-3. Review. Norwegian.
Transforming growth factor-beta and angiotensin in fibrosis and burn injuries.
Gabriel VA.
J Burn Care Res. 2009 May-Jun;30(3):471-81. Review.
Fibrillin in Marfan syndrome and tight skin mice provides new insights into transforming growth factor-beta regulation and systemic sclerosis.
Lemaire R, Bayle J, Lafyatis R.
Curr Opin Rheumatol. 2006 Nov;18(6):582-7. Review.
Severe fibrosis and increased expression of fibrogenic cytokines in the gastric wall of systemic sclerosis patients.
Manetti M, Neumann E, Milia AF, Tarner IH, Bechi P, Matucci-Cerinic M, Ibba-Manneschi L, Müller-Ladner U.
Arthritis Rheum. 2007 Oct;56(10):3442-7.
Pro- and anti-fibrotic effects of TGF-beta in scleroderma.
Sgonc R, Wick G.
Rheumatology (Oxford). 2008 Oct;47 Suppl 5:v5-7. Review.
Animal models of scleroderma: lessons from transgenic and knockout mice.
Derrett-Smith EC, Denton CP, Sonnylal S.
Curr Opin Rheumatol. 2009 Nov;21(6):630-5. Review.
Systemic sclerosis: current views of its pathogenesis.
Derk CT, Jimenez SA.
Autoimmun Rev. 2003 Jun;2(4):181-91. Review.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on